Fig. 3: CM-444 and CM-1758 induction of differentiation and anti-leukemic activity in vivo.

A ML-2 cells were pretreated in vitro with 260 nM of CM-444 or 210 nM of CM-1758 for 96 h. After verifying CD11b induction by flow cytometry, equal amounts of cells were injected subcutaneously in Rag2^−/− ɣc^−/− mice, and tumor volume was measured (n = 8). Error bars indicate the S.D. Statistical significance was calculated by a two-tailed Student’s t-test. B Schematic diagram of the in vivo CM-444 and CM-1758 treatment procedure and tumor volume curve of the ML-2 subcutaneous xenograft model in Rag2^−/− ɣc^−/− mice (n = 8). Error bars indicate the S.D. Statistical significance was calculated by a two-tailed Student’s t-test. C CD11b from tumors in an ML-2 subcutaneous model was measured by q-PCR (n = 5). Error bars indicate the S.D. Statistical significance was calculated by a two-tailed Student’s t-test. D Schematic diagram of the in vivo CM-444 and CM-1758 treatment procedure and Kaplan–Meier survival curve for evaluating the survival time of Rag2^−/− ɣc^−/− mice engrafted with MV4-11 cells after intravenous administration (n = 10). P-values assessed by log-rank. E CD11b levels in blood samples from an intravenous MV4-11 mouse model measured by flow cytometry (n = 7 for Control and CM-1758 group and n = 10 for CM-444 group). Error bars indicate the S.D. Statistical significance was calculated by a two-tailed Student’s t-test. Control: treatment with CM-444 or CM-1758 vehicle (80% saline, 10% Tween 20, and 10% DMSO); s.c.: subcutaneous; i.v.: intravenous. Source data are provided as a Source data file.